

New omicron subvariant largely evades neutralizing antibodies

October 14 2022





BA.2.75.2 escapes neutralizing antibodies. (A) Differences from BA.2 in BA.2.75 (orange), and BA.2.75.2 (red, underlined), depicted upon the SARS-CoV-2 BA.2 receptor binding domain (pdb:7UB0). Sensitivity of SARS-CoV-2 omicron sublineages and ancestral B.1 (D614G) to neutralization by monoclonal antibodies (B), and randomly sampled sera from blood donated in Stockholm, Sweden, between Nov 8–14, 2021 (n=25; C), April 11–17, 2022 (n=25; D), and Aug 29 to Sept 4, 2022 (n=25; E). Sera with neutralization less than 50% at the lowest dilution tested (20) are plotted as 20 (dotted line). IC50=50% inhibitory concentration. ID50=50% inhibitory dilution. *Indicates reversion. Credit: *The Lancet Infectious Diseases* (2022). DOI: 10.1016/S1473-3099(22)00663-6

A study at Karolinska Institutet shows that the coronavirus variant BA.2.75.2, an omicron sublineage, largely evades neutralizing antibodies in the blood and is resistant to several monoclonal antibody antiviral treatments. The findings, published in the journal *The Lancet Infectious Diseases*, suggest a risk of increased SARS-CoV-2 infections this winter, unless the new updated bivalent vaccines help to boost immunity in the population.

"While antibody immunity is not completely gone, BA.2.75.2 exhibited far more dramatic resistance than variants we've previously studied, largely driven by two mutations in the receptor binding domain of the spike protein," says the study's corresponding author Ben Murrell, assistant professor at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet.

The study shows that antibodies in random serum samples from 75 <u>blood</u> <u>donors</u> in Stockholm were approximately only one-sixth as effective at neutralizing BA.2.75.2 compared with the now-dominant variant BA.5. The serum samples were collected at three time points: In November last year before the emergence of omicron, in April after a large wave of infections in the country, and at the end of August to early September



after the BA.5 variant became dominant.

Only one of the clinically available monoclonal antibody treatments that were tested, bebtelovimab, was able to potently neutralize the new variant, according to the study. Monoclonal <u>antibodies</u> are used as antiviral treatments for people at high risk of developing severe COVID-19.

BA.2.75.2 is a mutated version of another omicron variant, BA.2.75. Since it was first discovered earlier this fall, it has spread to several countries but so far represents only a minority of registered cases.

Risk of increased infections

"We now know that this is just one of a constellation of emerging variants with similar mutations that will likely come to dominate in the near future," Ben Murrell says, adding "we should expect infections to increase this winter."

Some questions remain. It is unclear whether these new variants will drive an increase in hospitalization rates. Also, while current vaccines have, in general, had a protective effect against <u>severe disease</u> for omicron infections, there is not yet data showing the degree to which the updated COVID vaccines provide protection from these new variants. "We expect them to be beneficial, but we don't yet know by how much," Ben Murrell says.

More information: Daniel J Sheward et al, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies, *The Lancet Infectious Diseases* (2022). DOI: <u>10.1016/S1473-3099(22)00663-6</u>



Provided by Karolinska Institutet

Citation: New omicron subvariant largely evades neutralizing antibodies (2022, October 14) retrieved 10 May 2024 from <u>https://medicalxpress.com/news/2022-10-omicron-subvariant-largely-evades-neutralizing.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.